Mibg (I123) Curium Netherlands (Iodine (123i) Iobenguane)

Iobenguane I-123 mimics norepinephrine and is actively taken up by the norepinephrine transporter on sympathetic nerve endings. Once inside the cells, its radioactive iodine‑123 emits gamma photons that are captured by a gamma camera, producing detailed images of sympathetic nervous system distribution.

The prescribed activity for Mibg (I123) Curium Netherlands is determined by the ordering physician based on the patient’s age, weight, and the specific diagnostic indication. The exact administered dose is individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Mibg (I123) Curium Netherlands involves ionising radiation and is generally avoided in pregnancy unless the diagnostic benefit clearly outweighs fetal risk. Breastfeeding should be paused for a period recommended by the treating physician to prevent radiation exposure to the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mibg (I123) specifically targets the norepinephrine transporter, offering high specificity for adrenergic tissue. Compared with fluorodeoxyglucose (FDG) PET, it provides superior detection of catecholamine‑producing tumors such as neuroblastoma and pheochromocytoma, though it does not assess metabolic activity like FDG.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use and handled in a shielded environment by trained personnel to minimize radiation exposure.

Mibg (I123) is administered as a single intravenous injection by a qualified nuclear medicine professional. After injection, a waiting period of typically 15‑24 hours allows optimal tracer uptake before gamma‑camera imaging is performed.

Serious risks include severe allergic reactions (anaphylaxis), marked hypotension, radiation‑induced skin injury at the injection site, and potential thyroid dysfunction from iodine exposure. Proper patient screening and adherence to radiation safety protocols help mitigate these risks.

Patients with known severe allergy to iodine‑123 compounds, uncontrolled hypertension, significant cardiac arrhythmias, or those who are pregnant or breastfeeding without a clear clinical justification should not receive this radiopharmaceutical. Clinical judgment is essential for each individual case.